Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verrica Pharmaceuticals Inc. filings document the regulatory record for a Nasdaq-listed dermatology therapeutics company with common stock trading under VRCA. Its Form 8-K reports cover operating and financial results, material agreements, capital-structure actions and Nasdaq listing compliance matters, including disclosures related to a reverse stock split and bid-price compliance.
The company’s proxy and material-event filings also address governance, shareholder voting matters and collaboration arrangements tied to its YCANTH franchise. These filings provide formal disclosure on the company’s commercial product, dermatology pipeline, equity plans, security-holder rights and public-company reporting obligations.
Verrica Pharmaceuticals announced a press release reporting its financial results for the three- and six-month periods ended June 30, 2025 and disclosed details for a related conference call; that press release is furnished as Exhibit 99.1 to the current report. The filing also includes an interactive XBRL cover page file.
The company further disclosed that Nasdaq's Listing Qualifications Staff has determined the company has regained compliance with the bid price requirement under Nasdaq Listing Rule 5450(a)(1), indicating the company is currently meeting Nasdaq's listing standards for minimum bid price.
Verrica Pharmaceuticals Inc. (VRCA) filed an 8-K to disclose a Second Amendment to its March 2021 Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd.
- Up-front cash: Torii will pay Verrica an $8.0 million milestone tied to the ongoing global Phase 3 trial of YCANTH (VP-102) for common warts.
- Cost-sharing: The parties will continue to split trial expenses 50/50. Torii will advance the first $40.0 million of out-of-pocket costs; Verrica will subsequently reimburse Torii for half. If expenses exceed $40 million, Verrica will fund the overage (up to a stated cap) and Torii will reimburse 50% of that excess.
- Additional milestone: Torii agreed to a separate $10.0 million cash payment upon Japanese approval of YCANTH for molluscum contagiosum—paid in cash rather than as a trial-cost offset.
- Manufacturing rights: A technology-transfer program will allow Torii to manufacture the product. Until partial transfer is complete, Torii will buy commercial supply from Verrica at transfer pricing; thereafter Verrica will receive quarterly royalties in the high-single- to low-double-digit range.
- All other material terms of the original agreement remain unchanged.
The amendment improves Verrica’s near-term liquidity via non-dilutive funding, caps some development risk, and may accelerate commercial scale-up in Japan. A press release announcing the amendment (Exhibit 99.1) was issued on July 1, 2025.